Hilary Sherman
Papers
1
Total Citations
22
H-Index
1
About
Dr. Hilary Sherman is a leading figure in the advancement of preclinical drug absorption and permeability screening, with a primary focus on high-throughput automation. Her major contribution lies in revolutionizing cell-based ADME/Tox assays, specifically by transitioning labor-intensive Caco-2 and MDCK-MDR1 models from standard 24-well formats into efficient, automated 96-well platforms. Her seminal 2012 work, "Automation of Cell-Based Drug Absorption Assays in 96-Well Format Using Permeable Support Systems," which has garnered 22 citations, provided a critical framework for accelerating lead compound testing. By demonstrating that automated, higher-density systems could reliably generate essential permeability and transport data, Dr. Sherman directly addressed a key bottleneck in drug discovery, enabling faster and more cost-effective go/no-go decisions for potential therapeutics. Her work is foundational for researchers seeking to integrate robust, high-capacity screening into their early-stage pipelines, significantly impacting the efficiency of modern pharmaceutical development.
Research Focus
Key Achievements
Top Papers
- 1